RxDoctor Payments Data

Amanda Ferguson

Family · Kingston, TNNPI 1083931430

Payments from drug & device makers

$1,027in general payments, 2019–2025

Across 46 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$402
  • Johnson & Johnson$125
  • Merz North America, Inc.$112
  • Lilly USA, LLC$94
  • Pfizer$68
  • Dexcom, Inc.$53
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$1,027100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,027 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$90,075
Medicare patients
184
Services billed
3,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$89,119
EliquisApixaban85$84,606
OzempicSemaglutide69$84,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$65,753
MounjaroTirzepatide51$61,357
JanuviaSitagliptin Phosphate32$27,775
Tresiba Flextouch U-200Insulin Degludec24$19,134
TradjentaLinagliptin29$18,134
Tresiba Flextouch U-100Insulin Degludec17$17,246
XareltoRivaroxaban12$16,953
TrulicityDulaglutide14$15,310
LinzessLinaclotide12$13,203
EntrestoSacubitril/Valsartan12$11,836
Lantus SolostarInsulin Glargine,hum.Rec.Anlog70$11,566
MyrbetriqMirabegron14$7,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$20$107,254100 claims
PfizerEliquis$68$84,60685 claims
Novo NordiskOzempic$402$84,28169 claims
Lilly USA, LLCMounjaro, Trulicity$94$76,66765 claims
Johnson & JohnsonXarelto$125$16,95312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Kingston

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →